TWST · Twist Bioscience Corporation

The thesis

Twist Bioscience's growth as a data supplier for AI-driven antibody discovery shows up in its reported revenue. The shares have given back a large part of their autumn run, and new analyst coverage has split around the current price. The fiscal fourth-quarter report, expected around mid-November 2026, settles the case. It shows whether revenue clears the company's $123–124 million guide and whether adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, excluding specified items) reaches the promised breakeven.

The decline has continued since the last update. On split- and dividend-adjusted daily closes, the shares closed at $152.05 on 8 October 2026, after $166.97 on 6 October 2026. That is 25.8% below the $205.00 closing high of 5 October 2026. The three-month gain on the same closes has narrowed to 68.3%, and the 14-day relative strength index (RSI), a momentum gauge, read 44.1, which is neutral.

Two new analyst actions sit on either side of the price. Barclays kept its Overweight rating and raised its target to $215 on 7 October 2026, per Benzinga's ratings feed. Jefferies started coverage at Hold with a $150 target on 8 October 2026, per the same feed. The narrative is saturated: retail-trading sites restated the 16 September 2026 Eli Lilly TuneLab agreement several times on 5 October 2026, and the sessions since brought a Hold initiation and lower closes instead of new buyers. No company release since 16 September 2026 changes the business facts. The quarter under test closed on 30 September 2026.

Bullish and bearish views on Twist Bioscience Corporation

The bull case on Twist Bioscience Corporation (TWST), in brief: Growth is already in reported revenue. The bear case: The consensus target is far below the price.

Bull case

• Growth is already in reported revenue. Fiscal Q3 FY26 revenue was $118.4 million, up 23% year over year, per the 3 August 2026 Form 8-K. DNA Synthesis and Protein Solutions revenue rose 39% to $56.6 million, and gross margin was 52.8%.
• Guidance calls for a higher fourth quarter. The 3 August 2026 release guided fiscal Q4 revenue to $123–124 million with breakeven adjusted EBITDA. It set full-year FY26 revenue at $456–457 million with gross margin above 52%.
• The August raise removed funding pressure. Twist priced 3,125,000 shares at $96.00 on 4 August 2026 for $300.0 million of gross proceeds, per its pricing release and Form 424B5. MarketBeat put debt-to-equity at 0.03 on 6 October 2026.
• A named AI ordering channel exists. The 16 September 2026 agreement lets participants in Eli Lilly's TuneLab platform order Twist antibody-characterization services at preferred protocols and pricing, per the company's Business Wire release. No contract value was disclosed.
• The highest targets sit well above the price. Barclays raised its target to $215 on 7 October 2026, per Benzinga. Guggenheim raised its target to $212 from $107 on 1 October 2026, per GuruFocus, and Leerink Partners raised its target to $190 from $160 on 29 September 2026, per Benzinga.

Bear case

• The consensus target is far below the price. MarketBeat put the consensus target at $115.27 on 6 October 2026, from eight Buy, two Hold and two Sell ratings. UBS initiated at Neutral with a $144 target and BWS Financial at Sell with a $45 target on 9 September 2026.
• The newest initiation is neutral. Jefferies began coverage at Hold with a $150 target on 8 October 2026, per Benzinga, slightly under the $152.05 close that day.
• Two of the highest targets come from underwriters. Guggenheim Securities and Leerink Partners were lead underwriters of the August offering, with Goldman Sachs and William Blair, per the 4 August 2026 preliminary prospectus supplement.
• ARK Invest is a persistent seller. Investing.com and Benzinga reported on 6 October 2026 that ARK sold Twist across its ARKK and ARKG funds for a 21st consecutive session, about $18 million on 5 October 2026, while buying Recursion, Veracyte and Intellia.
• Insiders keep selling. MarketBeat, citing SEC Form 4 filings, reported tax-withholding sales on 2 October 2026 at $188.88 by insider Dennis Cho (9,514 shares) and chief accounting officer Robert Werner (1,482 shares), plus a sale by the chief executive under a Rule 10b5-1 plan.
• The business still loses money. Fiscal Q3 FY26 net loss was $35.1 million and adjusted EBITDA was a loss of $11.3 million, per the 3 August 2026 Form 8-K. The breakeven guide requires an $11.3 million swing in one quarter.

Price setup

The shares set an intraday 52-week high near $192 on 25 September 2026 and retreated that session, per Benzinga. They then touched $219.71 early on 6 October 2026 before falling 16.1% intraday, per Investing.com. The closing high is $205.00 on 5 October 2026, and the last close is $152.05 on 8 October 2026.

MarketBeat put the 50-day moving average at $138.77 and the 200-day moving average at $93.53 on 6 October 2026. The August offering priced at $96.00, close to the 200-day average. The price still sits above a rising 50-day average, so the run since August is intact on that measure even after the reversal.

Crowding is visible on several fronts: daily ARK sales through 5 October 2026, officer sales on 2 October 2026, a cluster of retail-site articles on 5 October 2026, and a quarterly report about five weeks out. A weekly close below $138, under the 50-day average, would end the uptrend that followed the August offering.

Catalysts, next 30 days

• ~24 October 2026, est. Announcement of the fiscal Q4 FY26 report date. Twist announced its fiscal 2024 date on 24 October 2024.
• ~16 November 2026, est. (outside 30 days; the case turns on it). Fiscal Q4 FY26 results for July–September. The report tests revenue against the $123–124 million guide, adjusted EBITDA against breakeven, and is the first chance to put a number on TuneLab or other AI-customer orders and to set a fiscal 2027 outlook.

Elapsed catalysts

• Each trading day. ARK Invest's daily trade disclosures show whether the run of Twist sales that reached 21 sessions on 5 October 2026 continues. (passed 7d ago)

What would change the view

The case breaks if fiscal Q4 FY26 revenue comes in below $123 million or adjusted EBITDA stays negative. Both commitments were made on 3 August 2026, and missing either would show the AI-data demand has not yet reached the income statement at the promised pace. A report that gives no repeat-order or revenue figure for AI accounts, or describes TuneLab activity as pilots only, would weaken it further.

On price, a weekly close below $138, under the $138.77 50-day moving average MarketBeat reported on 6 October 2026, would mark the end of the post-offering uptrend.

The read would improve if revenue clears $124 million with adjusted EBITDA at or above breakeven, and if the fiscal 2027 outlook implies growth at or above the 23% reported for fiscal Q3. An end to ARK's daily selling would remove the most visible source of supply.

What it trades with

The medtech and diagnostics group, which includes GRAL, NTRA, ILMN, MYGN, QTRX, CDNA, RVTY and ISRG, has been heating in weekly readings since 27 September 2026 and was still heating on 9 October 2026. Twist's October fall happened while that group was strengthening, which points to stock-specific drivers: ARK flows and the unwinding of the TuneLab run. A stronger group therefore offers little support here. If the group cools while ARK keeps selling, the shares would face both pressures at once.

ARK's 6 October 2026 trades sold Twist while buying Recursion, Veracyte and Intellia, per Benzinga. That links Twist's near-term moves more closely to ARK's genomics-fund decisions and to AI drug-discovery sentiment than to diagnostic peers' earnings.